Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2024-03-18 00:00:00 ET · period of report 2019-09-10 · accession 0001415889-24-008316 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-18 | 2023-01-09 | MIRM | Longpre Lara | Chief DEVELOPMENT Off | S - Sale | $20.62 | -1,003 | 104.4K | -1.0% | -$20.7K | |
| 2024-03-18 | 2019-09-10 | MIRM | Longpre Lara | Chief DEVELOPMENT Off | P - Purchase | $10.64 | +965 | 105.4K | +0.9% | +$10.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-09 | S | D | 1,003 | $20.62 | 104,369 | D | — | — | |
| 2 | Common | Common Stock | 2019-09-10 | P | A | 965 | $10.64 | 105,372 | D | — | — | (F1) The weighted average purchase price for the transaction reported was $10.64, and the range of prices were between $10.20 and $10.8799. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |